# NR0B2

## Overview
NR0B2, also known as the small heterodimer partner (SHP), is a gene that encodes an atypical nuclear receptor protein, nuclear receptor subfamily 0 group B member 2. Unlike typical nuclear receptors, SHP lacks a DNA-binding domain, which classifies it as an orphan nuclear receptor. Instead, it functions primarily as a transcriptional corepressor, modulating the activity of other nuclear receptors through protein-protein interactions (Pawlak2012General; Weikum2018The). SHP is predominantly expressed in the liver, where it plays a critical role in regulating metabolic processes such as bile acid, cholesterol, and glucose homeostasis (CHANDA2008Molecular; Seol1996An). The protein's ability to form heterodimers with other nuclear receptors allows it to influence various metabolic pathways, making it a key player in maintaining metabolic balance (Prestin2017Functional). Additionally, SHP has been implicated in the pathogenesis of metabolic disorders and certain cancers, highlighting its clinical significance (Enya2008Mutations; Zhang2011Role).

## Structure
NR0B2, also known as the small heterodimer partner (SHP), is an atypical nuclear receptor characterized by its lack of a DNA-binding domain, which distinguishes it from other members of the nuclear receptor superfamily (Pawlak2012General). The primary structure of NR0B2 includes a ligand-binding domain (LBD), which is a common feature among nuclear receptors (Weikum2018The). The secondary structure of NR0B2 is composed of alpha helices, contributing to its overall stability and function (Weikum2018The).

The tertiary structure of NR0B2 involves a compact fold typical of nuclear receptors, allowing it to interact with other proteins through protein-protein interactions rather than direct DNA binding (Prestin2017Functional). This structural configuration enables NR0B2 to function as a transcriptional corepressor, modulating the activity of other nuclear receptors by forming heterodimers (Pawlak2012General).

NR0B2 may undergo post-translational modifications such as phosphorylation, which can influence its activity and interactions with other proteins (Weikum2018The). These structural features and modifications are crucial for its role in regulating various metabolic pathways, including bile acid and glucose homeostasis (Prestin2017Functional).

## Function
The NR0B2 gene encodes the small heterodimer partner (SHP), an orphan nuclear receptor that lacks a DNA-binding domain but functions as a transcriptional corepressor. SHP is primarily active in the liver, where it plays a crucial role in regulating metabolic processes, including bile acid, cholesterol, and glucose homeostasis. It interacts with various nuclear receptors and transcription factors to modulate their activity, often repressing transcriptional activation (CHANDA2008Molecular; Seol1996An).

SHP is involved in the feedback regulation of bile acid synthesis. When bile acids activate the nuclear receptor FXR, SHP expression is induced, leading to the repression of CYP7A1, a key enzyme in bile acid biosynthesis. This interaction helps maintain cholesterol homeostasis by controlling the conversion of cholesterol to bile acids (CHANDA2008Molecular; Goodwin2000A).

In glucose metabolism, SHP inhibits transcriptional activities related to gluconeogenesis and insulin secretion, affecting genes like PEPCK and G6Pase. This regulation is essential for maintaining glucose homeostasis in the liver (CHANDA2008Molecular; Wei2011Feedback). SHP also plays a role in drug metabolism and steroidogenesis, highlighting its importance in maintaining metabolic balance and responding to physiological changes (CHANDA2008Molecular).

## Clinical Significance
Mutations and alterations in the NR0B2 gene, also known as SHP, have been linked to several metabolic disorders and cancers. In metabolic diseases, NR0B2 mutations are associated with type 2 diabetes mellitus, particularly in Japanese populations, where they contribute to insulin resistance and mild obesity (Enya2008Mutations). These mutations can lead to a loss of function, affecting the gene's role in lipid metabolism and insulin sensitivity (Enya2008Mutations). Variants of NR0B2 have also been linked to obesity, with specific mutations showing reduced functional activity in inhibiting transcriptional activity, which may influence insulin secretion and contribute to obesity (Echwald2004Mutation).

In cancer, NR0B2 acts as a tumor suppressor, with its expression often reduced in various cancers due to promoter hypermethylation. This downregulation is observed in hepatocellular carcinoma (HCC), where it leads to decreased tumor suppressive functions, such as inhibiting cellular growth and activating apoptosis (Zou2015New; Zhang2011Role). In clear cell renal cell carcinoma (ccRCC), NR0B2 suppression is also linked to promoter hypermethylation, suggesting a role in tumor development (Kudryavtseva2018Suppression). Additionally, frameshift mutations in NR0B2 have been identified in early-onset colorectal carcinomas, potentially contributing to cancer susceptibility through altered gene expression and protein interactions (Lam2020The).

## Interactions
The NR0B2 gene encodes the Small Heterodimer Partner (SHP), an orphan nuclear receptor that participates in various protein-protein interactions. SHP functions primarily as a transcriptional corepressor by interacting with other nuclear receptors, such as DAX1 (NR0B1), PXR (Pregnane X Receptor), and ERα (Estrogen Receptor alpha) (Iyer2007LXXLL; Kumar2021Nuclear). SHP forms homodimers and heterodimers with DAX1 through its LXXLL motifs and AF-2 domain, which are crucial for these interactions (Iyer2007LXXLL). These motifs are also essential for SHP's interaction with DAX1, as mutations in these regions significantly reduce binding affinity (Iyer2007LXXLL).

SHP interacts with PXR and ERα, repressing their transcriptional activities. Specific amino acid residues, such as R216, E204, and W206, are critical for these interactions, and mutations at these sites can diminish SHP's binding affinity (Kumar2021Nuclear). SHP can also modulate the chromatin binding of PXR and ERα during mitosis, affecting their nuclear localization and function (Kumar2021Nuclear). These interactions highlight SHP's role as a central hub in a network of nuclear receptor interactions, acting as a master negative switch to suppress the function of various nuclear receptors (Amoutzias2007A).


## References


[1. (Pawlak2012General) Michal Pawlak, Philippe Lefebvre, and Bart Staels. General molecular biology and architecture of nuclear receptors. Current Topics in Medicinal Chemistry, 12(6):486–504, March 2012. URL: http://dx.doi.org/10.2174/156802612799436641, doi:10.2174/156802612799436641. This article has 114 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/156802612799436641)

[2. (Echwald2004Mutation) Søren M. Echwald, Kirstine L. Andersen, Thorkild I.A. Sørensen, Lesli H. Larsen, Teis Andersen, Naoko Tonooka, Hideaki Tomura, Jun Takeda, and Oluf Pedersen. Mutation analysis ofnr0b2among 1545 danish men identifies a novel c.278g&gt;a (p.g93d) variant with reduced functional activity: genetic variation of humannr0b2. Human Mutation, 24(5):381–387, September 2004. URL: http://dx.doi.org/10.1002/humu.20090, doi:10.1002/humu.20090. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20090)

[3. (Amoutzias2007A) Gregory D Amoutzias, Elgar E Pichler, Nina Mian, David De Graaf, Anastasia Imsiridou, Marc Robinson-Rechavi, Erich Bornberg-Bauer, David L Robertson, and Stephen G Oliver. A protein interaction atlas for the nuclear receptors: properties and quality of a hub-based dimerisation network. BMC Systems Biology, July 2007. URL: http://dx.doi.org/10.1186/1752-0509-1-34, doi:10.1186/1752-0509-1-34. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1752-0509-1-34)

[4. (Lam2020The) Kuen Kuen Lam, Raman Sethi, Grace Tan, Swati Tomar, Michelle Lo, Carol Loi, Choong Leong Tang, Emile Tan, Poh San Lai, and Peh Yean Cheah. The orphan nuclear receptor <scp>nr0b2</scp> could be a novel susceptibility locus associated with microsatellite‐stable, <scp>apc</scp> mutation‐negative early‐onset colorectal carcinomas with metabolic manifestation. Genes, Chromosomes and Cancer, 60(2):61–72, October 2020. URL: http://dx.doi.org/10.1002/gcc.22904, doi:10.1002/gcc.22904. This article has 5 citations.](https://doi.org/10.1002/gcc.22904)

[5. (Zhang2011Role) Yuxia Zhang, Curt H. Hagedorn, and Li Wang. Role of nuclear receptor shp in metabolism and cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(8):893–908, August 2011. URL: http://dx.doi.org/10.1016/j.bbadis.2010.10.006, doi:10.1016/j.bbadis.2010.10.006. This article has 186 citations.](https://doi.org/10.1016/j.bbadis.2010.10.006)

[6. (Prestin2017Functional) Katharina Prestin, Maria Olbert, Janine Hussner, Henry Völzke, and Henriette E. Meyer zu Schwabedissen. Functional assessment of genetic variants located in the promoter of shp1 (nr0b2). Pharmacogenetics and Genomics, 27(11):410–415, November 2017. URL: http://dx.doi.org/10.1097/fpc.0000000000000310, doi:10.1097/fpc.0000000000000310. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/fpc.0000000000000310)

[7. (Wei2011Feedback) Dan Wei, Rongya Tao, Yao Zhang, Morris F. White, and X. Charlie Dong. Feedback regulation of hepatic gluconeogenesis through modulation of shp/nr0b2 gene expression by sirt1 and foxo1. American Journal of Physiology-Endocrinology and Metabolism, 300(2):E312–E320, February 2011. URL: http://dx.doi.org/10.1152/ajpendo.00524.2010, doi:10.1152/ajpendo.00524.2010. This article has 43 citations.](https://doi.org/10.1152/ajpendo.00524.2010)

[8. (Enya2008Mutations) Mayumi Enya, Yukio Horikawa, Eiji Kuroda, Kayoko Yonemaru, Naoko Tonooka, Hideaki Tomura, Naohisa Oda, Norihide Yokoi, Kazuya Yamagata, Nobuyuki Shihara, Katsumi Iizuka, Toshiji Saibara, Susumu Seino, and Jun Takeda. Mutations in the small heterodimer partner gene increase morbidity risk in japanese type 2 diabetes patients. Human Mutation, 29(11):E271–E277, November 2008. URL: http://dx.doi.org/10.1002/humu.20865, doi:10.1002/humu.20865. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20865)

[9. (CHANDA2008Molecular) Dipanjan CHANDA, Jeong-Hoh PARK, and Hueng-Sik CHOI. Molecular basis of endocrine regulation by orphan nuclear receptor small heterodimer partner. Endocrine Journal, 55(2):253–268, 2008. URL: http://dx.doi.org/10.1507/endocrj.k07e-103, doi:10.1507/endocrj.k07e-103. This article has 93 citations and is from a peer-reviewed journal.](https://doi.org/10.1507/endocrj.k07e-103)

[10. (Iyer2007LXXLL) Anita K. Iyer, Yao-Hua Zhang, and Edward R.B. McCabe. Lxxll motifs and af-2 domain mediate shp (nr0b2) homodimerization and dax1 (nr0b1)–dax1a heterodimerization. Molecular Genetics and Metabolism, 92(1–2):151–159, September 2007. URL: http://dx.doi.org/10.1016/j.ymgme.2007.06.009, doi:10.1016/j.ymgme.2007.06.009. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2007.06.009)

[11. (Seol1996An) Wongi Seol, Hueng-Sik Choi, and David D. Moore. An orphan nuclear hormone receptor that lacks a dna binding domain and heterodimerizes with other receptors. Science, 272(5266):1336–1339, May 1996. URL: http://dx.doi.org/10.1126/science.272.5266.1336, doi:10.1126/science.272.5266.1336. This article has 436 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.272.5266.1336)

[12. (Kumar2021Nuclear) Sudhir Kumar, Ramachandran Vijayan, Amit K. Dash, Samudrala Gourinath, and Rakesh K. Tyagi. Nuclear receptor shp dampens transcription function and abrogates mitotic chromatin association of pxr and erα via intermolecular interactions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1864(3):194683, March 2021. URL: http://dx.doi.org/10.1016/j.bbagrm.2020.194683, doi:10.1016/j.bbagrm.2020.194683. This article has 7 citations.](https://doi.org/10.1016/j.bbagrm.2020.194683)

[13. (Goodwin2000A) Bryan Goodwin, Stacey A. Jones, Roger R. Price, Michael A. Watson, David D. McKee, Linda B. Moore, Cristin Galardi, Joan G. Wilson, Michael C. Lewis, Matthew E. Roth, Patrick R. Maloney, Timothy M. Willson, and Steven A. Kliewer. A regulatory cascade of the nuclear receptors fxr, shp-1, and lrh-1 represses bile acid biosynthesis. Molecular Cell, 6(3):517–526, September 2000. URL: http://dx.doi.org/10.1016/S1097-2765(00)00051-4, doi:10.1016/s1097-2765(00)00051-4. This article has 2192 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/S1097-2765(00)00051-4)

[14. (Kudryavtseva2018Suppression) A. V. Kudryavtseva, K. M. Nyushko, A. R. Zaretsky, D. A. Shagin, A. F. Sadritdinova, M. S. Fedorova, M. V. Savvateeva, Z. G. Guvatova, E. A. Pudova, B. Y. Alekseev, A. A. Dmitriev, and A. V. Snezhkina. Suppression of nr0b2 gene in clear cell renal cell carcinoma is associated with hypermethylation of its promoter. Molecular Biology, 52(3):414–418, May 2018. URL: http://dx.doi.org/10.1134/S0026893318030081, doi:10.1134/s0026893318030081. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1134/S0026893318030081)

[15. (Zou2015New) An Zou, Sarah Lehn, Nancy Magee, and Yuxia Zhang. New insights into orphan nuclear receptor shp in liver cancer. Nuclear Receptor Research, 2015. URL: http://dx.doi.org/10.11131/2015/101162, doi:10.11131/2015/101162. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.11131/2015/101162)

[16. (Weikum2018The) Emily R. Weikum, Xu Liu, and Eric A. Ortlund. The nuclear receptor superfamily: a structural perspective. Protein Science, 27(11):1876–1892, October 2018. URL: http://dx.doi.org/10.1002/pro.3496, doi:10.1002/pro.3496. This article has 314 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pro.3496)